Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Apellis Pharmaceuticals: Clinical Trials & FDA Approval Profile

Apellis Pharmaceuticals (Global / Institutional) sponsors 19 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 4 active protocols (3 recruiting now), 12 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)15.8%
Median Closed Enrollment vs National (145 pts)76 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Apellis Pharmaceuticals
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)19
Active Pipeline (Recruiting Now)4 (3)
Completed vs Stopped Early12 / 3 (15.8%)
Median Closed Actual Enrollment76 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Apellis Pharmaceuticals
Hospital Research SiteLocationShared Protocols
Northwestern Memorial and Lurie Cancer CenterChicago, IL6
Emory Winship Cancer InstituteAtlanta, GA4
USC Norris Comprehensive Cancer Center and Keck MedicineLos Angeles, CA4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Apellis Pharmaceuticals
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04901936A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Phase IIRECRUITING
NCT07215390A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics ofPhase IIRECRUITING
NCT05067127Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex MembranoproliferativPhase IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Apellis Pharmaceuticals Interactive Dossier, benchmark peers in Ophthalmology and Sensory, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI